Department of Obstetrics and Gynecology

Medicine & Life Sciences

1. Endometriosis 100%
2. Taiwan 96%
3. Ovarian Epithelial Carcinoma 87%
4. Myoma 86%
5. Induced Pluripotent Stem Cells 85%
6. Uterine Myomectomy 82%
7. Adenomyosis 80%
8. Carcinoma 65%
9. Ovarian Neoplasms 60%
10. Uterine Cervical Neoplasms 59%
11. Pregnancy 58%
12. Fallopian Tubes 56%
13. Neoplasms 54%
14. Laparoscopy 51%
15. Endometrial Neoplasms 50%
16. Systematic Reviews 49%
17. Estrogens 49%
18. Retrospective Studies 46%
19. Cystectomy 46%
20. Morcellation 44%
21. Cisplatin 43%
22. Cohort Studies 42%
23. Leiomyoma 41%
24. Ovarian Teratoma 41%
25. Suburethral Slings 38%
26. Therapeutics 37%
27. Stress Urinary Incontinence 34%
28. Teratoma 33%
29. Cyclooxygenase 2 33%
30. Gonadotropin-Releasing Hormone 33%
31. beta-D-galactoside alpha 2-6-sialyltransferase 32%
32. Gestational Age 32%
33. Recurrence 31%
34. Fallopian Tube Neoplasms 30%
35. Survival 30%
36. Operative Time 30%
37. Drug Therapy 29%
38. Levonorgestrel 28%
39. Abdominal Pain 27%
40. Sarcoma 26%
41. Shoulder Pain 26%
42. dienogest 26%
43. Menorrhagia 26%
44. Squamous Cell Carcinoma 26%
45. Carcinosarcoma 25%
46. Gynecology 25%
47. Endometrium 24%
48. Paclitaxel 24%
49. Maintenance 24%
50. Randomized Controlled Trials 24%
51. Gynecologic Surgical Procedures 23%
52. Uterus 22%
53. Acute Liver Failure 22%
54. Doppler Ultrasonography 21%
55. Epithelial-Mesenchymal Transition 21%
56. Ovary 21%
57. Dysmenorrhea 21%
58. Polycystic Ovary Syndrome 21%
59. Lymph Nodes 20%
60. Wounds and Injuries 20%
61. Hysterectomy 20%
62. Laparotomy 20%
63. Platinum 20%
64. Breast Neoplasms 20%
65. Obstetrics 19%
66. Estrogen Receptors 19%
67. Hepatocyte Nuclear Factor 1-beta 19%
68. Cervix Uteri 19%
69. Tertiary Care Centers 18%
70. Aurora Kinase B 18%
71. Urodynamics 18%
72. Salpingo-oophorectomy 18%
73. Ultrasonography 18%
74. Vaginal Hysterectomy 18%
75. Hepatocytes 17%
76. Control Groups 17%
77. trans-1,2-dihydrobenzene-1,2-diol dehydrogenase 17%
78. Raloxifene Hydrochloride 17%
79. Placenta 17%
80. Adenomyoma 17%
81. Postoperative Pain 17%
82. Endometrial Stromal Sarcoma 17%
83. Shoulder 17%
84. Fibroblasts 17%
85. Ifosfamide 17%
86. Mesenchymal Stem Cells 17%
87. Aurora Kinase A 16%
88. Wound Healing 16%
89. Therapeutic Uses 16%
90. First Pregnancy Trimester 16%
91. Disease-Free Survival 16%
92. Liver 16%
93. Sialyltransferases 16%
94. Apoptosis 16%
95. Pelvic Organ Prolapse 16%
96. Neoplasm Metastasis 15%
97. Pregnancy Outcome 15%
98. Clear Cell Adenocarcinoma 15%
99. Blood Volume 15%